Wholesale distribution of prescription pharmaceuticals across Japan. Procurement and distribution of medical equipment, materials, and clinical diagnostic reagents. Now — the numbers.
This is an established company with proven profits.
No real growth (4% a year).
If every debt were paid off today, $1.9B would still be left in the vault — a solid cushion for hard times.
The market pays 13.7× for every dollar of annual profit — cheap, which is either an opportunity or a warning.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
There is $1.9B in the vault; even if every debt were paid off, $1.9B would remain.
It pays out $0.43 per share each year — regular cash for whoever holds the stock.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
As the slice kept from each sale thins out, so does the profit. Council score: 3/10.
The price action doesn’t yet back an upward turn. Council score: 3/10.
We don’t have a report card for this stock yet — the data isn’t mature enough to grade. No grade is information too: it means the evidence is thin.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.